Literature DB >> 33469693

Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar grades using conventional and T1-weighted DCE-MRI.

Mamta Gupta1, Abhinav Gupta1, Virendra Yadav2, Suhail P Parvaze3, Anup Singh2, Jitender Saini4, Rana Patir5, Sandeep Vaishya5, Sunita Ahlawat6, Rakesh Kumar Gupta7.   

Abstract

PURPOSE: This retrospective study was performed on a 3T MRI to determine the unique conventional MR imaging and T1-weighted DCE-MRI features of oligodendroglioma and astrocytoma and investigate the utility of machine learning algorithms in their differentiation.
METHODS: Histologically confirmed, 81 treatment-naïve patients were classified into two groups as per WHO 2016 classification: oligodendroglioma (n = 16; grade II, n = 25; grade III) and astrocytoma (n = 10; grade II, n = 30; grade III). The differences in tumor morphology characteristics were evaluated using Z-test. T1-weighted DCE-MRI data were analyzed using an in-house built MATLAB program. The mean 90th percentile of relative cerebral blood flow, relative cerebral blood volume corrected, volume transfer rate from plasma to extracellular extravascular space, and extravascular extracellular space volume values were evaluated using independent Student's t test. Support vector machine (SVM) classifier was constructed to differentiate two groups across grade II, grade III, and grade II+III based on statistically significant features.
RESULTS: Z-test signified only calcification among conventional MR features to categorize oligodendroglioma and astrocytoma across grade III and grade II+III tumors. No statistical significance was found in the perfusion parameters between two groups and its subtypes. SVM trained on calcification also provided moderate accuracy to differentiate oligodendroglioma from astrocytoma.
CONCLUSION: We conclude that conventional MR features except calcification and the quantitative T1-weighted DCE-MRI parameters fail to discriminate between oligodendroglioma and astrocytoma. The SVM could not further aid in their differentiation. The study also suggests that the presence of more than 50% T2-FLAIR mismatch may be considered as a more conclusive sign for differentiation of IDH mutant astrocytoma.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Astrocytoma; MR imaging; Machine learning; Oligodendroglioma; T1-weighted DCE-MRI

Year:  2021        PMID: 33469693     DOI: 10.1007/s00234-021-02636-8

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  43 in total

Review 1.  Oligodendroglial neoplasms: current concepts, misconceptions, and folklore.

Authors:  A Perry
Journal:  Adv Anat Pathol       Date:  2001-07       Impact factor: 3.875

2.  Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Authors:  Hikaru Sasaki; Magdalena C Zlatescu; Rebecca A Betensky; Loki B Johnk; Andrea N Cutone; J Gregory Cairncross; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2002-01       Impact factor: 3.685

3.  T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.

Authors:  Sohil H Patel; Laila M Poisson; Daniel J Brat; Yueren Zhou; Lee Cooper; Matija Snuderl; Cheddhi Thomas; Ana M Franceschi; Brent Griffith; Adam E Flanders; John G Golfinos; Andrew S Chi; Rajan Jain
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

Review 4.  Chemotherapy for the treatment of oligodendroglial tumors.

Authors:  O Chinot
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

5.  Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging.

Authors:  Hyun Jung Yoon; Kook Jin Ahn; Song Lee; Jin Hee Jang; Hyun Seok Choi; So Lyung Jung; Bum Soo Kim; Shin Soo Jeun; Yong Kil Hong
Journal:  Neuroradiology       Date:  2017-05-26       Impact factor: 2.804

6.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.

Authors:  Soonmee Cha; Tarik Tihan; Forrest Crawford; Nancy J Fischbein; Susan Chang; Andrew Bollen; Sarah J Nelson; Michael Prados; Mitchel S Berger; William P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

Review 7.  Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.

Authors:  Herbert H Engelhard; Ana Stelea; Arno Mundt
Journal:  Surg Neurol       Date:  2003-11

Review 8.  Epidemiology.

Authors:  Kyle M Walsh; Hiroko Ohgaki; Margaret R Wrensch
Journal:  Handb Clin Neurol       Date:  2016

Review 9.  New perspectives for the diagnosis and treatment of oligodendroglioma.

Authors:  M J van den Bent
Journal:  Expert Rev Anticancer Ther       Date:  2001-10       Impact factor: 4.512

Review 10.  Imaging of oligodendroglioma.

Authors:  Marion Smits
Journal:  Br J Radiol       Date:  2016-02-05       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.